{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:28:30Z","timestamp":1778812110572,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014148","name":"Centro Hospitalar Universit\u00e1rio do Porto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0016\/0011"],"award-info":[{"award-number":["RD16\/0016\/0011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ijantimicag.2020.105887","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T02:18:46Z","timestamp":1578449926000},"page":"105887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study"],"prefix":"10.1016","volume":"55","author":[{"given":"Sergio","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Melo-Cristino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida F.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valqu\u00edria","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Raquel","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmano","family":"Ramalheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00edsa","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Diogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"P\u00e1ssaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1697-4737","authenticated-orcid":false,"given":"Laura","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-3173","authenticated-orcid":false,"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105887_bib0001","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0002","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997-2016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0003","unstructured":"European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2017. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC. 2018."},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0004","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3389\/fmicb.2018.02834","article-title":"Molecular epidemiology and risk factors of carbapenemase-producing Enterobacteriaceae isolates in Portuguese Hospitals: results from European Survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE)","volume":"9","author":"Manageiro","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0005","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1128\/AAC.05065-14","article-title":"Predominance of KPC-3 in a Survey for Carbapenemase-Producing Enterobacteriaceae in Portugal","volume":"59","author":"Manageiro","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0006","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0007","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0008","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0009","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonian.d."},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0010","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0011","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. 2020."},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0012","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.8.4.557","article-title":"beta-Lactamases in laboratory and clinical resistance","volume":"8","author":"Livermore","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0014","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pan-drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/jac\/dkv355","article-title":"A single-day point-prevalence study of faecal carriers in long-term care hospitals in Madrid (Spain) depicts a complex clonal and polyclonal dissemination of carbapenemase-producing Enterobacteriaceae","volume":"71","author":"Ruiz-Garbajosa","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0016","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","article-title":"Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015","volume":"20","author":"Albiger","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0017","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1128\/AAC.02961-14","article-title":"First description of OXA-48 carbapenemase harbored by Escherichia coli and Enterobacter cloacae from a single patient in Portugal","volume":"58","author":"Manageiro","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0018","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0019","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijantimicag.2019.02.004","article-title":"Activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study","volume":"53","author":"Garc\u00eda-Fern\u00e1ndez","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0021","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijantimicag.2018.03.014","article-title":"Which non-carbapenem antibiotics are active against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae?","volume":"52","author":"Bouxom","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.ijantimicag.2020.105887_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00675-18","article-title":"In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different \u03b2-lactam resistance phenotypes","volume":"62","author":"Robin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.105887_bib0023","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"Del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0024","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jac\/dkx453","article-title":"Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane\/tazobactam and comparators, and molecular epidemiology of carbapenemase producers","volume":"73","author":"Giani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105887_bib0025","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:27:50Z","timestamp":1778549270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0924857920300261"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105887","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105887"}}